The Latest Cardiac and Vascular News
Successful procedures initiate U.S. limited market release MIAMI LAKES, Fla., June 16, 2022 /PRNewswire/ — Cordis, a global leader in cardiovascular technologies, today announced the first-in-human use of the Radianz Radial Peripheral System™ by Jihad Mustapha, MD, FACC, FSCAI at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, Michigan. The Radianz Radial Peripheral System™ solution […]
MENLO PARK, Calif., April 5, 2022 /PRNewswire/ — Endovascular Engineering (“E2”), a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), today announced the closing of a $15 million Series A1 financing. The financing was co-led by Santé Ventures and Cordis, who were joined by […]
Completes the RADIANZ Radial Peripheral System™; signals Cordis’ renewed investment in innovation MIAMI LAKES, Fla., March 10, 2022 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T. RADIANZ™ Vascular Stent System, a self-expanding stent purposefully engineered for radial peripheral procedures. […]
Cordis continues leadership team buildout with seasoned healthcare finance officer MIAMI LAKES, Fla., Dec. 16, 2021 /PRNewswire/ — Cordis, a global interventional cardiovascular technology company, today announced that Christopher Scully has joined the organization as Chief Financial Officer. He will be responsible for leading the company’s financial and IT functions and will play an instrumental […]
Globally recognized interventional cardiologist is the latest addition to a growing leadership team MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization’s mission to differentiate itself as a technological leader and value-based […]
Matthew Muscari takes the helm of global marketing and American sales as Cordis pursues path of transformation and growth MIAMI LAKES, Fla., Nov. 2, 2021 /PRNewswire/ — Cordis, a global interventional vascular technology company, today announced that Matthew Muscari will assume the role of President of the Americas, heading a leadership team responsible […]
DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. […]
DUBLIN, Ohio, March 12, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working capital accounts. The transaction is expected to close […]
DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the body’s […]
DUBLIN, Ohio, November 28, 2018 — Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system designed […]
